IMR Press / FBL / Special Issues / tumor_induced_immune_suppression

Tumor-Induced Immune Suppression: Mechanisms, Consequences and Cancer Immunotherapy

Submission deadline: 15 August 2022
Special Issue Editor
  • Theresa L. Whiteside, PhD
    Departments of Pathology, Immunology, Otolaryngology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, USA
    Interests: Clinical cancer immunology; Cancer immunotherapy; Exosomes as cancer biomarkers; Extracellular vesicles; Immuno-oncology; Immune suppression in cancer; Regulatory T cells; Tumor-derived exosomes; Tumor microenvironment
Special Issue Information

Dear Colleagues,

This issue of Frontiers of Bioscience will feature a series of contributions addressing the role of tumor-induced immune suppression in cancer escape from the host immune system and in cancer immunotherapy. Despite significant, recent success of the immune checkpoint blockade (ICB) in treatment of patients with melanoma and other solid tumors, many patients fail to respond to immune therapies used alone or in combination with conventional chemo/radiotherapies. Further, initially favorable responses are often followed by a rapid relapse, as the tumor develops resistance to therapy. In an effort to define the mechanisms driving tumor resistance to therapy, current studies are increasingly focused on dissecting the intimate relationship that exists between the tumor and immune cells in the tumor microenvironment (TME). Perturbations in this relationship, whether induced by the tumor or immune cells, lead to reprogramming of the TME that profoundly affects cancer progression and outcome. Many different mechanisms appear to drive reprogramming in the TME; accordingly, the targeting of molecular/genetic/cellular pathways mediating tumor/immune cell interactions has emerged as a promising strategy for changing pro-tumor to anti-tumor milieu of the TME.

With increasing interest in improving beneficial effects of immune therapies, attention has been directed at overcoming or eliminating tumor-induced immune suppression. Immunotherapy aims at the restoration of vigorous and effective anti-tumor immune responses able to arrest tumor progression. However, as every tumor presents a distinct immunosuppressive profile, the selection of strategies able to convert “cold” to “hot” tumors may be difficult, requiring a deeper understanding of the processes that take place in the TME during cancer development and progression. In this Special Issue, we hope to generate a discussion of how to rationally select and optimize cancer immunotherapies in the face of the remarkably efficient and highly personalized immunoinhibitory environments most tumors create. The objective is to gather and review the available information about (1) the role tumor-induced immune suppression plays in immunotherapy outcome, and (2) the capability of tumors to evade/respond to immunotherapy. Such knowledge could serve as a basis for the rational design of future highly successful immunotherapy strategies. Clearly, a better understanding of the nature and mechanisms underpinning tumor-induced immune suppression is necessary if we are to successfully deliver immunotherapy to cancer patients, especially those with an advanced disease.

Prof. Theresa L. Whiteside

Guest Editor

Keywords
Tumor microenvironment
Immune suppression
Tumor resistance to therapy
Tumor immune escape
TME reprogramming
Immunotherapy
Tumor infiltrating cells
Tumor-derived exosomes
Biomarkers
Liquid biopsy
Cytokines
Checkpoint inhibitors
Cancer progression
Metastasis
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top